145 related articles for article (PubMed ID: 20606645)
1. Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-β gene.
Hasegawa Y; Kinoh H; Iwadate Y; Onimaru M; Ueda Y; Harada Y; Saito S; Furuya A; Saegusa T; Morodomi Y; Hasegawa M; Saito S; Aoki I; Saeki N; Yonemitsu Y
Mol Ther; 2010 Oct; 18(10):1778-86. PubMed ID: 20606645
[TBL] [Abstract][Full Text] [Related]
2. BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
Morodomi Y; Yano T; Kinoh H; Harada Y; Saito S; Kyuragi R; Yoshida K; Onimaru M; Shoji F; Yoshida T; Ito K; Shikada Y; Maruyama R; Hasegawa M; Maehara Y; Yonemitsu Y
Mol Ther; 2012 Apr; 20(4):769-77. PubMed ID: 22314292
[TBL] [Abstract][Full Text] [Related]
3. Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus.
Miyagawa Y; Araki K; Yamashita T; Tanaka S; Tanaka Y; Tomifuji M; Ueda Y; Yonemitsu Y; Shimada H; Shiotani A
Head Neck; 2019 Sep; 41(9):2873-2882. PubMed ID: 30969451
[TBL] [Abstract][Full Text] [Related]
4. Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Tanaka Y; Araki K; Tanaka S; Miyagawa Y; Suzuki H; Kamide D; Tomifuji M; Uno K; Kimura E; Yamashita T; Ueda Y; Shiotani A
Mol Cancer Ther; 2019 Aug; 18(8):1430-1438. PubMed ID: 31171582
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Sendai virus-induced tumor-specific immunoresponses suppress "simulated metastasis" of squamous cell carcinoma in an immunocompetent mouse model.
Tanaka Y; Araki K; Tanaka S; Miyagawa Y; Suzuki H; Kamide D; Tomifuji M; Uno K; Harada E; Yamashita T; Ueda Y; Inoue M; Shiotani A
Head Neck; 2019 Jun; 41(6):1676-1686. PubMed ID: 30620422
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
7. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
8. uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.
Raghu H; Nalla AK; Gondi CS; Gujrati M; Dinh DH; Rao JS
Mol Oncol; 2012 Feb; 6(1):33-47. PubMed ID: 22177802
[TBL] [Abstract][Full Text] [Related]
9. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Kinoh H; Inoue M; Komaru A; Ueda Y; Hasegawa M; Yonemitsu Y
Gene Ther; 2009 Mar; 16(3):392-403. PubMed ID: 19037241
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
[TBL] [Abstract][Full Text] [Related]
12. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
13. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
16. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
17. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
18. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
19. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
[TBL] [Abstract][Full Text] [Related]
20. New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
Kinoh H; Inoue M
Front Biosci; 2008 Jan; 13():2327-34. PubMed ID: 17981715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
